HHS Restructuring: Major Workforce Reductions Under Secretary Robert F. Kennedy Jr. Promises $1.8 Billion Savings Frank Dolan March 31, 2025
SV Health Investors Unveils Endlyz Therapeutics: A New Hope for Parkinson’s Disease Treatments Frank Dolan March 31, 2025
Alcon Acquires Majority Stake in Aurion Biotech: What This Means for Corneal Therapy Development Frank Dolan March 31, 2025
Equillium’s Itolizumab Fails Phase 3 Trial for aGVHD: What’s Next for the Biotech Company? Frank Dolan March 31, 2025
Nkarta Biotech Restructures Amid Financial Pressures: Major Layoffs as it Targets Autoimmune Therapy Frank Dolan March 31, 2025
How Trump’s Tariff Strategy Could Boost Domestic Drug Manufacturing While Straining Generic Producers Frank Dolan March 31, 2025
Novo Nordisk’s $1 Billion Bet on Obesity Drug: Industry Shakeups at Lexicon, Arbutus, and CRISPR Frank Dolan March 31, 2025
Game-Changer in Lung Cancer Treatment: Merck’s Injectable Keytruda Shows Promising Phase 3 Trial Results Frank Dolan March 31, 2025
Eli Lilly’s Kisunla Faces EMA Setback: Can the Alzheimer’s Drug Overcome ARIA Concerns? Frank Dolan March 31, 2025
Massive 20% Job Cuts at FDA: What It Means for Health Policies and Public Safety Frank Dolan March 31, 2025
FDA Expands Pluvicto Use: A Game-Changer in Metastatic Prostate Cancer Treatment Frank Dolan March 31, 2025
Merck KGaA Invests $85 Million in Abbisko Therapeutics: A Strategic Move to Boost Oncology Portfolio with Pimicotinib Frank Dolan March 31, 2025
Bluebird Bio Receives $45 Million Buyout Offer from Ayrmid Ltd: A Game Changer in Gene Therapy? Frank Dolan March 31, 2025
Alumis and Acelyrin: Exploring Reverse Mergers Ahead of IPOs in Biopharma Sector Frank Dolan March 31, 2025
Revolutionizing Hemophilia Treatment: FDA Approves Qfitlia, A Game-Changing RNA Drug by Sanofi Frank Dolan March 31, 2025
Leadership Shakeup: Julianne Bruno Steps Down as COO of CRISPR Therapeutics Amid Industry Changes Frank Dolan March 30, 2025
Novo Nordisk Teams Up with Lexicon Pharmaceuticals: A Game-Changer in Obesity Treatment Worth $1 Billion Frank Dolan March 30, 2025
BioNTech’s Breakthrough Bispecific Antibody Combines Checkpoint Inhibition and VEGF-A Targeting for Lung Cancer Treatment Frank Dolan March 30, 2025
EMA Rejects Eli Lilly’s Kisunla: Serious Side Effects Outweigh Benefits in Alzheimer’s Treatment Frank Dolan March 30, 2025
DBV Technologies Secures $306 Million for Peanut Allergy Patch: Major Moves in Biotech and Pharma Frank Dolan March 30, 2025
